Health
Jin Medical (NASDAQ: ZJYL) Expands into the Manufacturing Field of lifestyle Beauty Products, Collaborates in Research and Development of Three Beauty and Body Products, Securing Market Orders
CHANGZHOU, China, Aug. 31, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("the Company" or "JinMed") (NASDAQ: ZJYL) is the world's leading provider of rehabilitation equipment. Recently, JinMed announcedit has expand into the field of manufacturing lifestyle beauty products by establishing ...
2023-08-31 22:37
1530
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023
BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative therapies for rare diseases...
2023-08-31 15:15
3943
Tycoon Group Announces 2023 Interim Results
The Group's Revenue Hits New Heights Net profit for 1H2023 increased more than 2.8 times YoY Benefited from the Full Resumption of Normal Travel Revenue Continues to Generate Profit in Future Results Highlights * Since the full resumption of normal travel between Hong Kong, Macau and Mainland C...
2023-08-31 13:28
4039
Zylox-Tonbridge's ZENFlow Tiger™ LD PTA Dilatation Catheter Receives ANVISA Marketing Approval
HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as "ZENFlow Tiger™"), a product independently ...
2023-08-31 11:31
1670
LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'
* Announces Human Rights and Environmental Management Charter Alongside Annual Implementation Strategies within its Mid-to-Long-term ESG Roadmap * Strengthens Eco-friendly Policies, Including Greenhouse Gas Reduction Plans from the Initial Factory Design Stage SEOUL, South Korea, Aug. 30, 20...
2023-08-31 09:00
1754
Jacobio Pharma Announces 2023 Interim Results
BEIJING, SHANGHAI and BOSTON, Aug. 30, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results. During the period, the company recorded revenue ofRMB 40.3 million even as it continued to accelerate multip...
2023-08-30 21:45
3840
GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community
With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewswire/ --All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value. On Aug. 30th, the company held the "Donate...
2023-08-30 16:05
1378
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...
2023-08-30 14:19
1405
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC
NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approv...
2023-08-30 11:00
1808
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue ofRMB21.395 bi...
2023-08-30 10:53
2764
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...
2023-08-30 08:03
2259
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised$32 million in Series A round of financing c...
2023-08-30 08:00
3653
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...
2023-08-30 00:02
1214
Datasea Announces Strategic Partnership with Sales and Marketing Firm for the Launch of Intelligent Acoustic Skin Repair Robot
BEIJING, Aug. 29, 2023 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology corporation engaged in converging and innovative business segment for intelligent acoustics technology inChina today announced that Shuhai Information Technology Co., Ltd. ("Shuh...
2023-08-29 21:57
1848
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) loca...
2023-08-29 20:00
1344
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference
SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthca...
2023-08-28 20:00
1251
Harbour BioMed Announces 2023 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
2023-08-28 17:08
2440
Meet Kuushy: Sit your way to better health
The smart cushion is paired with an AI-enabled Posture Coach that provides personalised prompts for users to adjust and correct their posture effectively SINGAPORE, Aug. 28, 2023 /PRNewswire/ -- Poor posture can lead to a whole range of problems – from neck and back pains to even heartburn and co...
2023-08-28 16:46
1472
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its first antib...
2023-08-28 16:30
1478
Zylox-Tonbridge Reveals 2023 Interim Financial Results: Revenue Surges 50.7% YOY to 230 Million Yuan, Gross Profit Climbs to 171 Million Yuan
HANGZHOU, China, Aug. 27, 2023 /PRNewswire/ -- On August 23rd, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its financial results for the first half of 2023. The Company's revenue reached230 million yuan, repr...
2023-08-28 11:42
2250
Week's Top Stories
Most Reposted
Mastercard goes OTP-free in APAC for faster, safer online transactions
[Picked up by 326 media titles]
2024-11-06 09:00Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 309 media titles]
2024-11-12 09:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 284 media titles]
2024-11-12 11:00
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
13117
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10117
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7458
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6173
